Shire’s Cinryze receives EU approval for use in paediatric HAE patients

Shire has announced that its drug Cinryze has been approved in Europe in three new indications for children with hereditary angioedema (HAE).

The European Commission has approved a label extension broadening the use of Cinryze for the routine prevention of angioedema attacks in children aged six and older with severe and recurrent attacks of HAE who are intolerant to or insufficiently protected by oral prevention therapies, or who are inadequately managed with repeated acute treatment.

It is the first and only HAE treatment with this indication in paediatric patients. Additionally, the drug is now also approved for the treatment and pre-procedure prevention of angioedema attacks in children aged two years and above.

Cinryze has been approved since 2011 for these indications in adults and adolescents aged 12 to 17 years with HAE, a rare genetic disorder characterised by swelling in certain parts of the body, most notably the extremities and abdomen.

Dr Philip Vickers, head of research and development at Shire, said: "We believe the future of HAE means preventing attacks before they happen, and are proud to now be able to offer the first long-term preventative treatment for paediatric patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.